RAPT Therapeutics

GSK offices
#Allergy #GSK #Mergers and acquisitions #Monoclonal antibodies #RAPT Therapeutics

GSK expands food allergy pipeline with RAPT purchase

GSK has entered a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and immunologic diseases.   The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens.  Under the terms of the… Read More

#Business & Investment #News

Child with eczema
#Atopic dermatitis #Clinical trial #Clinical trial design #Innovaderm Research #Phase I trial #RAPT Therapeutics

Clinical data supports oral treatment for atopic dermatitis

A new drug for atopic dermatitis (AD) has demonstrated a positive clinical effect and improvements in various efficacy endpoints after four weeks of treatment. The Phase Ia/IIb study was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 surface receptor occupancy of zelnecirnon in eligible… Read More

#News